Charles River Laboratories International In (CRL) - FREE Research Report

Geller Jorg who is Corporate Executive VP at Charles River Laboratories International In sold 893 shares at $47.17 on Oct. 8, 2013. Following this transaction, the Corporate Executive VP owned 54,192 shares meaning that the stake was reduced by 1.62% with the 893 share transaction.

The shares most recently traded at $46.35, down $0.82, or 1.76% since the insider transaction. Historical insider transactions for Charles River Laboratories International In go as follows:

  • 4-Week # shares sold: 5,958
  • 12-Week # shares sold: 26,805
  • 24-Week # shares sold: 32,825

The average volume for Charles River Laboratories International In has been 353,500 shares per day over the past 30 days. Charles River Laboratories International In has a market cap of $2.3 billion and is part of the health care sector and drugs industry. Shares are up 22.76% year to date as of the close of trading on Friday.

Charles River Laboratories International, Inc., together with its subsidiaries, provides research models and associated services, and outsourced preclinical services to accelerate the drug discovery and development process. The company has a P/E ratio of 22.5. Currently there are 4 analysts that rate Charles River Laboratories International In a buy, 1 analyst rates it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CRL - FREE

TheStreet Quant Ratings rates Charles River Laboratories International In as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Charles River Laboratories International In Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

7 Bargain-Basement Stocks That Could Rebound in 2017

This Year's Jewels in Last Year's Junk

Gun Stocks Are a Risky Play in 2017 -- Here's Why

Jim Cramer's 'Mad Money' Recap: Don't Worry About a Little Market Detour

'Mad Money' Lightning Round: Wynn Resorts vs. MGM, Ford vs. General Motors